AARTIPHARM
AARTIPHARM
AARTIPHARM · NSE
₹990.7
-3.31% (-₹33.9)
Prev. close
₹1,024.6
Volume
3,49,082
Delivery %
50.8%
As of
20 Nov 2026
Price history
Raja Venkatraman · NeoTrader · 11 Feb 2025, 05:30 IST
“Recommends buying Aarti Pharmalabs above ₹742 with a stop loss at ₹725 and a target of ₹825. The stock delivered stable Q3 results despite volatility, and its resilience suggests a strong breakout as buying momentum builds, with RSI above 70 indicating sustained upward trends.”
Target ₹825Stop ₹725Stopped out · 14 Feb 2025
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Bullish on Aarti Pharmalabs with a target price of ₹1,160, based on 24 times its estimated FY29 EPS of ₹48. Expects earn…” | Angel One AnalysisAngel One | Aarti Pharmalabs Ltd | PENDING | ||||
| “Recommends buying Aarti Pharmalabs at ₹804.85 with a target of ₹860 and a stop loss at ₹777. Also, advises buying Mazago…” | Sumeet BagadiaChoice Equity Broking | Aarti Pharmalabs | PENDING | ||||
| “Recommends buying Aarti Pharmalabs at ₹774.3 with a target of ₹830 and a stop loss at ₹725, citing a technical breakout.” | Sumeet BagadiaChoice Equity Broking | Aarti Pharmalabs Ltd | MISS | ||||
| “Recommends buying Aarti Pharmalabs today at ₹808.9, targeting ₹865, with a stop loss at ₹780, based on strong technical …” | Sumeet BagadiaChoice Equity Broking | Aarti Pharmalabs Ltd | MISS | ||||
| “Bullish on Aarti Pharmalabs Ltd, recommending a buy above ₹742 with a target of ₹825 and a stop loss at ₹725. The stock …” | Raja VenkatramanNeoTrader | Aarti Pharmalabs Ltd | MISS | ||||
| “Recommends buying Aarti Pharmalabs above ₹742 with a stop loss at ₹725 and a target of ₹825. The stock delivered stable …” | Raja VenkatramanNeoTrader | Aarti Pharmalabs Ltd | MISS | ||||
“Recommends buying Aarti Pharmalabs above ₹742 with a stop loss at ₹725 and a target of ₹825. The stock delivered stable Q3 results despite volatility, and its resilience suggests a strong breakout as buying momentum builds, with RSI above 70 indicating sustained upward trends.” How this call is judged A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open. Entry: ₹742, as stated. Target ₹825, stop ₹725, as stated. No time frame is stated, so it is tracked until a close reaches ₹825 or ₹725: there is no fixed window. The stop ₹725 was reached on a close before the target ₹825. Miss. The grader's working: R3 TRADE_SETUP: entered ₹791 on 2025-02-17 (stated entry ₹742, BREAKOUT entry, filled); stop ₹725 breached at close ₹718.1 on 2025-03-03. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open. (03 Mar 2025) | |||||||
| “Bullish on Aarti Pharmalabs, recommending a buy at ₹740.85 with a stop loss at ₹715 and a target price of ₹790. The stoc…” | Sumeet BagadiaChoice Equity Broking | Aarti Pharmalabs | HIT | ||||
About Aarti Pharmalabs Limited
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, ophthalmologic, antidepressant medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates, such as xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. It serves pharmaceutical, nutraceutical, and beverage industries. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Rashesh Chandrakant Gogri
Headquarters
Mumbai
Employees
2,421
Website
aartipharmalabs.comExchange
View on NSE ↗Key stats
Market cap
₹8,401.49 Cr
P/E ratio (TTM)
32.8
Dividend yield
0.43%
EPS (TTM)
₹28.29
Beta (1Y · daily vs NIFTY 50)
1.20
Beta (5Y · monthly vs NIFTY 50)
0.75
Shares float
4.99 Cr
EPS · quarter ended Sept 2026
₹7.87
Financial Performance
01 · Financials
EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Revenue for FY25 and FY26: the figure the company printed, which its own totals confirm and the series' figure did not. Revenue for FY22: from the company's own statements, which the series had none for.
02 · Earnings Per Share (EPS)
FY22: the EPS the company printed, added because it is on the same share count as the other years.
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss — as filed
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹1,202.46 Cr | ₹1,947.55 Cr | ₹1,857.50 Cr | ₹2,123.50 Cr | ₹1,829.19 Cr | |
| ₹1,047.08 Cr | ₹1,686.78 Cr | ₹1,557.01 Cr | ₹1,762.81 Cr | ₹1,601.47 Cr | |
Profit before share of profit/ (loss) of joint ventures, exceptional | — | — | — | ₹360.69 Cr | ₹227.72 Cr |
Share of profit/(loss) of joint ventures | — | — | — | — | ₹8.00 Cr |
Profit before exceptional items and tax (3+4) | ₹155.38 Cr | ₹260.77 Cr | ₹300.49 Cr | ₹360.69 Cr | ₹235.72 Cr |
Exceptional Items gain/(Loss) | — | — | — | — | ₹-2.79 Cr |
Profit before tax (5+6) | ₹155.38 Cr | ₹260.77 Cr | ₹300.49 Cr | ₹360.69 Cr | ₹232.92 Cr |
(a) Current Tax | ₹27.33 Cr | ₹55.98 Cr | ₹58.84 Cr | ₹72.20 Cr | ₹43.05 Cr |
MAT Credit Entitlement | ₹1.13 Cr | — | — | — | — |
(b) Earlier Year Tax | — | ₹3.13 Cr | ₹-3.06 Cr | ₹-4.70 Cr | ₹-88.06 L |
(c) Deferred Tax | ₹4.68 Cr | ₹8.17 Cr | ₹27.82 Cr | ₹20.78 Cr | ₹16.05 Cr |
Total Tax Expenses (a to c) | ₹33.13 Cr | ₹67.28 Cr | ₹83.59 Cr | ₹88.28 Cr | ₹58.21 Cr |
Profit for the year (7-8) | ₹122.25 Cr | ₹193.49 Cr | ₹216.90 Cr | ₹272.40 Cr | ₹174.71 Cr |
| ₹129.32 Cr | ₹190.05 Cr | ₹216.45 Cr | ₹262.65 Cr | ₹168.47 Cr | |
Basic | 13.49 | 21.35 | 23.93 | 30.06 | 19.27 |
Diluted | 13.49 | 21.35 | 23.93 | 30.04 | 19.25 |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
09 · Balance Sheet — as filed
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹2,039.90 Cr | ₹2,244.02 Cr | ₹2,582.11 Cr | ₹2,902.43 Cr | ₹3,481.71 Cr | |
| ₹1,011.75 Cr | ₹1,081.02 Cr | ₹1,236.46 Cr | ₹1,584.24 Cr | ₹2,084.41 Cr | |
| ₹1,028.15 Cr | ₹1,163.01 Cr | ₹1,345.64 Cr | ₹1,318.19 Cr | ₹1,397.29 Cr | |
| ₹1,386.48 Cr | ₹1,558.49 Cr | ₹1,757.04 Cr | ₹1,989.91 Cr | ₹2,124.60 Cr | |
(a) Equity Share Capital | ₹25.00 L | ₹45.31 Cr | ₹45.31 Cr | ₹45.32 Cr | ₹45.33 Cr |
Equity Share Capital pending allotment upon scheme of arrangment | ₹45.31 Cr | — | — | — | — |
(b) Other Equity | ₹1,340.92 Cr | ₹1,513.17 Cr | ₹1,711.73 Cr | ₹1,944.59 Cr | ₹2,079.28 Cr |
| ₹653.42 Cr | ₹685.54 Cr | ₹825.07 Cr | ₹912.52 Cr | ₹1,357.10 Cr | |
| ₹72.76 Cr | ₹84.91 Cr | ₹130.68 Cr | ₹259.45 Cr | ₹419.53 Cr | |
| ₹580.66 Cr | ₹600.62 Cr | ₹694.39 Cr | ₹653.07 Cr | ₹937.57 Cr | |
TOTAL EQUITY AND LIBILITIES (I+II+III) | ₹2,039.90 Cr | ₹2,244.02 Cr | ₹2,582.11 Cr | ₹2,902.43 Cr | ₹3,481.71 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
10 · Cash Flow Statement — as filed
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹-71.15 Cr | ₹11.51 Cr | ₹-16.90 Cr | ₹1.80 Cr | |
| ₹250.12 Cr | ₹216.35 Cr | ₹330.14 Cr | ₹261.93 Cr | |
| ₹-157.80 Cr | ₹-214.56 Cr | ₹-412.48 Cr | ₹-430.72 Cr | |
| ₹-163.46 Cr | ₹9.72 Cr | ₹65.43 Cr | ₹170.58 Cr | |
Cash and Cash Equivalent at the beginning of the year | — | ₹12.12 Cr | — | — |
Opening Balance of Cash and Cash Equivalents | ₹83.27 Cr | — | ₹23.63 Cr | ₹6.73 Cr |
Closing Balance of Cash and Cash Equivalents | ₹12.12 Cr | ₹23.63 Cr | ₹6.73 Cr | ₹8.53 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Jan 23 | Mar 23–Jun 23(2Q) | Sep 23 | Dec 23–Jun 24(3Q) | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 44.16% | 45.98% | 46.30% | 46.46% | 46.10% | 44.66% | 44.29% | 43.72% | 42.88% | 43.10% | 43.08% | 42.86% |
| Public | 55.84% | 54.02% | 53.70% | 53.54% | 53.90% | 55.34% | 55.71% | 56.28% | 57.12% | 56.90% | 56.92% | 57.14% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Aarti Pharmalabs Limited | ₹8,342.09 Cr | ₹926.5 | 32.5 | 3.93 | 8.2% | 0.36 | -14.3% | +9.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Index membership
2 indices
Aarti Pharmalabs rises 2.95% in Tuesday's session
Global Banking & Finance Review · 5 days ago
Aarti Pharmalabs targets 8,800 tonnes, pauses xanthine expansion
Multibagg AI · 18 days ago